Epilepsy is defined as a diverse set of neurological disorders characterized by seizures. These seizures occur due to abnormal electrical activity in the brain. Factors that may lead to epilepsy include, but are not limited to, brain trauma, gene mutations, strokes, brain cancer, and extensive drug and alcohol use. Seizures occur due to a large release of glutamate, which causes a spread of excitation throughout the brain, which propagates the electrical signal and can lead to neuronal death. Myoclonic epilepsy is characterized by seizures that result in rapid, jerk-like movements and can affect the face, limbs, or axial musculature. Juvenile myoclonic epilepsy is an epilepsy syndrome characterized by myoclonic jerks, generalized tonic-clonic seizures, and sometimes, absence seizures. The EFHC1 gene is an important gene associated with juvenile myoclonic epilepsy. About 50 million people have epilepsy, with 80% of that population located in developing countries. It is possible to control epilepsy with medicine, but many cases may require surgery in order to relieve symptoms.
Myoclonic Epilepsy, Juvenile Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Myoclonic Epilepsy, Juvenile below!
For more information on how to use Laverne, please read the How to Guide.
We have 759 products for the study of Myoclonic Epilepsy, Juvenile that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Myoclonic Epilepsy, Juvenile is also known as Adolescent Myoclonic Epilepsy, Epilepsy, Juvenile Myoclonic, Janz Syndrome, Jme (juvenile Myoclonic Epilepsy), Juvenile Myoclonic Epilepsies.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.